Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO StudyLigang Xing, Yueyin Pan, Yuankai Shi, et al.
Radiation Oncology (London, England)|January 23, 2024
A PET/CT radiomics model for predicting distant metastasis in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric studyLu Yu, Zhen Zhang, HeQing Yi, et al.
International Journal of Radiation Oncology, Biology, Physics|November 21, 2020
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 TrialLigang Xing, Gang Wu, Luhua Wang, et al.
Cancer Biology & Medicine|May 22, 2026
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH)Lisha Shen, Dongqing Lv, Ke-Jing Tang, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Cancer Cell|March 6, 2026
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan, Yuping Sun, Qiming Wang, et al.
Targeted Oncology|May 3, 2026
Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA StudyLigang Xing, Jinming Yu, Xiangjiao Meng, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
The New England Journal of Medicine|May 29, 2026
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion MutationsCaicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
Pageof 18